Ani Pharmaceuticals (ANIP) Receivables (2012 - 2026)

Ani Pharmaceuticals has disclosed Receivables across 15 years of filings, most recently posting $274.5 million for Q2 2026.

• In Q2 2026, Receivables rose 21.63% year-over-year to $274.5 million; the TTM figure through Jun 2026 stood at $274.5 million (up 21.63% YoY), while the FY2025 annual figure was $281.1 million, up 26.77% from the prior year.
• Receivables came in at $274.5 million for Q2 2026 at Ani Pharmaceuticals, up from $255.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $281.1 million in Q4 2025 to a low of $131.6 million in Q1 2022.
• Average Receivables over 5 years is $197.1 million, with a median of $176.8 million recorded in 2023.
• Year-over-year, Receivables jumped 62.35% in 2022 and slipped 4.9% in 2023.
• Over 5 years, Receivables stood at $170.4 million in 2022, then declined by 4.9% to $162.1 million in 2023, then surged by 36.8% to $221.7 million in 2024, then gained by 26.77% to $281.1 million in 2025, then decreased by 2.35% to $274.5 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $274.5 million in Q2 2026, $255.4 million in Q1 2026, and $281.1 million in Q4 2025.